As researchers explore potential treatments for systemic lupus erythematosus (SLE), mesenchymal stem cells (MSCs) have gained attention for their immunomodulatory properties. Rather than relying on direct cell transplantation, studies have focused on MSCs’ secretome (MSCS).
A meta-analysis of nine randomized controlled trials (n=485 patients) assessed the effectiveness of MSCS in SLE. Results indicated that MSCS therapy significantly reduced SLE Disease Activity Index (SLEDAI) scores, demonstrating a measurable improvement in disease activity.
Additionally, patients receiving MSCS therapy showed decreased anti-dsDNA antibody levels and increased complement C3 levels, both of which are key markers of immune function in SLE. Importantly, MSCS treatment was generally well-tolerated, with no reports of serious adverse events.
These findings support the therapeutic potential of MSCS in SLE management. Understanding the mechanisms behind MSCS and its interaction with the immune system may provide a foundation for future cell-free therapies in autoimmune disease treatment.
